Introduction
Despite established therapy for chronic CHF, including diuretics and an angiotensin-converting enzyme (ACE) inhibitor, some patients inevitably remain symptomatic. The Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM)-Added study 1 demonstrated significant improvement of symptoms and reduction in cardiovascular death and CHF hospitalisation with candesartan added to standard therapy (all patients were on ACE inhibitors and 55% were on beta-blockers), compared with placebo. Moreover, this benefit was seen irrespective of baseline therapy.
However, patients recruited into randomised controlled trials may differ, or may be perceived to differ, from those seen in routine practice. The clinician may also be reluctant to add another agent in patients already receiving a diuretic, ACE inhibitor and beta-blocker, despite clear evidence of efficacy, as illustrated in this case report.
Case Report
A 63-year-old overweight man with CHF (New York Heart Association [NYHA] class III) associated with reduced left ventricular ejection fraction (LVEF 36%) and chronic obstructive pulmonary disease (COPD) was considered for entry to a randomised controlled trial of drug therapy in CHF. His medical condition is summarised in Table 1 . At the time of study entry, he was receiving ramipril 5 mg/day, furosemide 50 mg/day and aspirin 100 mg/day. Treatment with this regimen was continued but at follow-up six months later the patient was still symptomatic (NYHA class III) and moderately hypertensive (blood pressure 140/92 mmHg, heart rate 82 beats/minute), with an elevation of circulating levels of brain natriuretic peptide (BNP, 490 pg/mL) and a low-density lipoprotein cholesterol (LDL-C) value of 3.6 mmol/L. The dosage of ramipril was increased to 10 mg/day; bisoprolol was added after one week, starting at 1.25 mg/day and increasing bi-weekly to a Nine months after the first visit, the patient was hospitalised for dyspnoea associated with atrial fibrillation (AF, mean ventricular rate 96 beats/minute). There was evidence of pulmonary congestion on chest X-ray. The patient underwent electrical cardioversion and was treated with intravenous furosemide (his COPD and impaired glucose tolerance were considered contraindications to the use of beta-blockers by the attending clinician), resulting in improvement in dyspnoea.
Case report
However, the patient was subsequently readmitted with worsening heart failure, precipitated by an episode of AF. The patient was then established on a more complete pharmacological regimen, incorporating ramipril 10 mg/day, furosemide 25 mg/day, bisoprolol 5 mg/day (and aspirin) in addition to candesartan, this last starting at a low dose of 4 mg/day and increasing every two weeks to the maximum tolerated dose (16 mg/day in this patient). Amiodarone 300 mg/day, decreasing to 100 mg/day after 10 days, was also prescribed for control of the arrhythmia. At follow-up eight months later, the patient's symptoms were well controlled, as evident by improvement in NYHA class (from class III to II) and LVEF and reduction in BNP levels (Table 1) .
Discussion and Conclusion
This case report confirms the important role of polypharmacy in the management of patients with moderate to severe CHF.
In the routine clinical setting, clinicians may have safety concerns relating to the addition of an ARB to existing CHF therapy with an ACE inhibitor and beta-blocker. Subgroup analyses of the Valsartan Heart Failure Trial (Val-HeFT) suggest-ed that this patient group actually fared worse when valsartan was introduced. 2 However, data from CHARM-Added 1 clearly showed the consistent efficacy of candesartan irrespective of baseline CHF therapy, and this has been recognised by the recent revision of the European Society of Cardiology guidelines for the management of CHF. 3 Further, the use of ARBs in patients with CHF seems to be associated with a significant reduction in occurrence of AF. 4, 5 Adherence to treatment guidelines for chronic HF is strongly correlated with patient outcome. 6 Therefore, clinicians should strive to implement guideline recommendations for the management of CHF, to ensure optimal patient outcome in routine clinical practice. 
